Mon panier

CD94

CD94 Informations sur la molécule

Nom anglaisNatural killer cells antigen CD94Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleKLRD1,Killer Cell Lectin Like Receptor D1,Killer Cell Lectin-Like Receptor Subfamily D, Member 1,CD94 Antigen,Killer Cell Lectin-Like Receptor Subfamily D Member 1,NK Cell Lectin-Like Receptor Subfamily D
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisNatural killer cells antigen CD94
Alias de la cibleKLRD1,Killer Cell Lectin Like Receptor D1,Killer Cell Lectin-Like Receptor Subfamily D, Member 1,CD94 Antigen,Killer Cell Lectin-Like Receptor Subfamily D Member 1,NK Cell Lectin-Like Receptor Subfamily D
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

CD94 Liste de produits

  • Attribut

    Protein (5)Antibody (1)

  • Bibliothèque de produits

    En ligne (6)

  • Espèces

    Human (2)Rhesus macaque (1)Rat (1)Mouse (2)

  • Étiquette

    Mouse IgG Fc Tag (1)His Tag (4)- (1)

  • Marqueur

    Unconjugated (5)PE Labeled (1)

CD94Contexte de la molécule

CD94(Natural killer cells antigen CD94) is also known as KLRD1, KP43, NK cell receptor, Killer cell lectin-like receptor subfamily D member 1. CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

CD94Alias de la molécule

CD94,KLRD1,KP43,NK cell receptor

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
DibotatugDR-01Phase 2 ClinicalDren Bio IncAlopecia Areata; Autoimmune Diseases of the Nervous System; Enteropathy-Associated T-Cell Lymphoma; Leukemia; Leukemia, Large Granular Lymphocytic; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Vitiligo
Details
JV-394JV-394Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterNeoplasms
Details

Avis sur les produits

  • Informations sur la molécule
  • Liste de produits
  • Avis sur les produits
  • Informations sur les médicaments cliniques